Later Line Therapeutic Decisions in Metastatic HCC
Later Line Therapeutic Decisions in Metastatic HCC
February 2014
- A 63-year old male with HBV
- ECOG=0
- Child-Pugh A; platelet count 230,000 cells/mcL
- Bilirubin 1.0 mg/dL; Albumin 3.5 g/dL
- CT scan revealed liver lesions, 1 is 2-cm; 1 is 5-cm both in the right lobe
- No extrahepatic disease
- Biopsy confirmed HCC diagnosis
- AFP=5400 IU/ml
- Tumors were resected with RO margin
August 2016
- Imaging showed recurrence in the liver, metastatic disease in the lungs
- Therapy was initiated with sorafenib 400 mg BID
- Therapy was well-tolerated
April 2017
- Radiographic progression with multiple lung metastases
- ECOG=0
- Therapy with regorafenib initiated at 160 mg
- Starting dose was well-tolerated, patient experienced some fatigue
Hope Beyond Surgery: Optimizing Care for Cholangiocarcinoma
February 15th 2024In an interview for Cholangiocarcinoma Awareness Day, Domenech Asbun, MD, discussed how the management of cholangiocarcinoma continues to evolve and addressed unmet needs in early detection and systemic therapy.
Read More
Durvalumab/Bevacizumab/TACE Significantly Extends Survival in HCC
February 6th 2024In an interview with Targeted Oncology, Bruno Sangro, MD, PhD, discussed the potential durvalumab, bevacizumab, and TACE has to set a new standard-of-care among patients with unresectable hepatocellular carcinoma.
Read More
Regorafenib Discontinuation More Likely With Poor Liver Function in Liver Cancer
January 19th 2024Patients with unresectable hepatocellular carcinoma and poor liver function were more likely to experience serious adverse effects leading to regorafenib treatment discontinuation, researchers have found.
Read More
